Table 1 Attributes and levels included in the DCE
Attribute | Formulation | Levels | Description of levels |
|---|---|---|---|
Type of treatment | The treatment consists of… | hESCsa | Cells taken from donated fertilized eggs. The cells have been multiplied and directed to produce dopamine. |
iPS cellsb | Your own/donated cells (e.g. blood cells) that have been multiplied and directed to produce dopamine. | ||
Electric stimulation | An implanted electrode with thin wire and stimulator that stimulates the brain. | ||
Drug | Drugs for Parkinson’s disease. | ||
Aim of treatment | The aim of the treatment is to… | Relieve symptoms | Improve function and well-being without affecting the development of the disease. As the disease progresses, doses usually need to be increased to obtain sufficient relief. |
Slow down disease progression | Affects the development of the disease so that the disease develops more slowly than it would have if you had not been treated. | ||
Repair damage caused by disease | Affects disease progression and restores functions lost due to your Parkinson’s disease. | ||
Available knowledge and experience of treatment | Number of patients that have received the treatment is… | 50 | After clinical research studies, the treatment has been approved for treatment against Parkinson’s disease. A total of 50 people have received the treatment. |
500 | After clinical research studies, the treatment has been approved for treatment against Parkinson’s disease. A total of 500 people have received the treatment. | ||
5000 | After clinical research studies, the treatment has been approved for treatment against Parkinson’s disease. A total of 5000 people have received the treatment. | ||
Effect on symptoms | Treatment effect on symptoms (for example, balance difficulties, tremors, depression, and dementia). The proportion that achieves sufficient function and well-being to at the moment not needing additional/different treatment for Parkinson’s is… | 2 out of 10 will get enough effectiveness | Out of 10 who receive the treatment, 2 people achieve sufficient function and well-being to not currently need additional/different treatment for Parkinson’s. |
5 out of 10 will get enough effectiveness | Out of 10 who receive the treatment, 5 people achieve sufficient function and well-being to not currently need additional/different treatment for Parkinson’s. | ||
8 out of 10 will get enough effectiveness | Out of 10 who receive the treatment, 8 people achieve sufficient function and well-being to not currently need additional/different treatment for Parkinson’s. | ||
Risk for severe side effects | The risk that the treatment causes a serious side effect that has a negative lasting effect on function and well-being is… | 20 out of 1000 | Out of 50 people who start the treatment, 1 person suffers some kind of serious side effect. |
10 out of 1000 | Out of 100 people who start the treatment, 1 person suffers some form of serious side effect. | ||
1 out of 1000 | Out of a thousand people who start the treatment, 1 person suffers some kind of serious side effect. |